Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: PP14 • ACR Convergence 2023
Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease
Natasha Trehan¹ and Naomi Abrahams², ¹University of Ottawa, Take a Pain Check Foundation, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Naomi was diagnosed with Juvenile Idiopathic Arthritis (JIA) at the age of 18, after enduring 3 years of misdiagnoses. Similarly, Natasha received a diagnosis…
Abstract Number: 0357 • ACR Convergence 2023
Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting
Pamela F. Weiss¹, Nicolino Ruperto², Erhard Quebe-Fehling³, Alexis Shew⁴, Luminita Pricop⁵, Christelle Pieterse³ and Hermine Brunner⁶, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, St. Louis, MO, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The juvenile spondyloarthritis disease activity index (JSpADA) is a disease activity assessment tool developed for children with juvenile psoriatic arthritis (JPsA) and enthesitis related…
Abstract Number: 0377 • ACR Convergence 2023
Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis
Melissa Mannion¹, Monica Aswani², Kristine Hearld², Emily Smitherman², Livie Huie³ and Jeffrey R Curtis⁴, ¹University of Alabama at Brimingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: The goal of treatment for patients with juvenile idiopathic arthritis (JIA) is inactive or minimal disease activity and escalating medication for active disease is…
Abstract Number: 1658 • ACR Convergence 2023
Title: Inflammatory Arthritis Across the Age-Spectrum: Single-Cell Profiling of the Inflamed Synovium in Children with Juvenile Idiopathic Arthritis
Chrissy Bolton¹, Christopher Mahony², Charlotte Smith², Vicky Alexiou³, Huong Nguyen³, Patricia Reis-Nisa², Søren Lomholt⁴, Annie Hackland², Sugrah Sultan⁵, Klaudia Kupiec³, Sunit Davda⁶, Charlene Foley⁶, Calliope Dendrou¹, Elizabeth C Rosser⁷, Accelerating Medicines Partnership Program RA SLE Network⁸, Anna Helena Jonsson⁹, Fan Zhang¹⁰, Michael Brenner¹¹, Soumya Raychaudhuri⁹, Christopher Buckley¹, Manigandan Thyagarajan⁵, Zishan Shiekh⁵, Sandrine Compeyrot-Lacassagne⁶, Samantha Chippington⁶, Mark Coles¹, Eslam Al-Abadi⁵, Andrew Filer², Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium¹², Lucy R Wedderburn³ and Adam Croft², ¹University of Oxford, Oxford, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³UCL Great Ormond Street Institute of Child Health, London, United Kingdom, ⁴Aarhus University, Aarhus, Denmark, ⁵Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, ⁶Great Ormond Street Hospital, London, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Colorado, Aurora, CO, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²MRC, Birmingham, United Kingdom
Background/Purpose: Understanding the unique and shared pathogenic processes between childhood-onset and adult-onset inflammatory arthritides is needed to guide more effective drug development and their application…
Abstract Number: 0358 • ACR Convergence 2023
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort
Esraa Eloseily¹, Autumn Clark¹, Min-Lee Chang², MaryEllen Riordan³, alan Russell⁴, Marc Natter⁵, Sherry Thornton⁶, Yukiko Kimura⁷ and Grant Schulert¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Boston Children's Hospital, Boston, MA, ³Hackensack Meridian Health, Hackensack, NJ, ⁴Duke Clinical Research Institute, Duke, NC, ⁵Harvard Medical School, Boston, MA, ⁶Cincinnati Children's Hospital, Cincinnati, OH, ⁷Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem with urgent unmet needs including prevalence, pathogenesis, disease…
Abstract Number: 0378 • ACR Convergence 2023
Characteristics of Macrophage Activation Syndrome in Systemic JIA Patients Receiving Anakinra as First-line Treatment
Remco Erkens¹, Laura Huber¹, Anouk Verwoerd¹, Greta Rogani¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Wineke Armbrust³, Elizabeth Legger⁴, Sylvia Kamphuis⁵, Ellen Schatorjé⁶, Esther Hoppenreijs⁷, Joost Swart⁸, Marc Jansen¹, Jorg van Loosdregt¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University Medical Hospital Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁶University Medical Center Radboud, Nijmegen, Netherlands, ⁷Radboud University Medical Center, Nijmegen, Netherlands, ⁸Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe inflammatory disease with auto-inflammatory characteristics. The introduction of targeted biologic therapies has revolutionized the treatment and…
Abstract Number: 1660 • ACR Convergence 2023
Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways
Mariana Correia Marques¹, Zuoming Deng², Navid Chowdhury², Elizabeth Schmitz³, Alana Platukus⁴, Stephen Brooks⁵, Carol Lake², Ly-Lan Bergeron², Michelle Millwood² and Michael Ombrello⁶, ¹National Institute of Arthritis & Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), St. Louis, MO, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Philadelphia, PA, ⁵Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skins Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Still’s disease (systemic juvenile idiopathic arthritis in children, adult-onset Still’s disease in adults) is an enigmatic inflammatory condition that affects people of all ages.…
Abstract Number: 0360 • ACR Convergence 2023
Increasing the Etanercept Dose in Juvenile Idiopathic Arthritis Patients: Does It Help Reaching the Treatment Target? A Post-hoc Analysis of the Best4Kids Randomised Clinical Trial
Bastiaan van Dijk¹, Sytske Anne Bergstra¹, Merlijn van den Berg², Dieneke Schonenberg-Meinema², Lisette van Suijlekom-Smit², Marion van Rossum³, Yvonne Koopman⁴, Rebecca Ten Cate¹, CF Allaart¹, Danielle Brinkman¹ and Petra Hissink Muller¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center | Reade, Amstelveen, Netherlands, ⁴HagaZiekenhuis Juliana Children's Hospital, The Hague, Netherlands
Background/Purpose: The relation between etanercept dose and clinical outcomes of juvenile idiopathic arthritis (JIA) is unclear. Most studies only evaluated doses up to 0.8 mg/kg/week…
Abstract Number: 0379 • ACR Convergence 2023
Clinical Evolution of Patients Diagnosed of Juvenile Idiopathic Arthritis After the Transitional Care Consultation
Alba Maria Torrat Noves¹, Rebeca Perpiñan Perez², Jose Ivorra Cortes¹, Elena Grau Garcia¹, Daniel Ramos Castro¹, Pablo Francisco Muñoz Martínez³, Laura Mas Sanchez⁴, Carmen Riesco Barcena¹, Anderson Victor Huaylla Quispe¹, Samuel Leal Rodriguez¹, Belen Villanueva Mañez¹, Iago Alcantara Alvarez¹, Isabel Martinez Cordellat¹, Luis Gonzalez Puig¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Elvira Vicens Bernabeu¹, Ernesto Tovar Sugrañes¹, Marta De la Rubia Navarro⁴, Hikmat Charia¹, Ines Canovas Olmos¹, Carmen Najera Herranz¹ and Jose Andres Roman Ivorra⁵, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Universidad Catolica de Valencia San Vicente Martir, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Sagunto, Spain, ⁴Rheumatology Department. HUP La Fe, Valéncia, Spain, ⁵Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses a group of chronic arthritis that begin in childhood. According to the International League of Associations for Rheumatology (ILAR)…
Abstract Number: 1662 • ACR Convergence 2023
Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency
Jemy Varghese¹, Scott Canna¹, Emily Landy², Laurence Eisenlohr¹, Elise Peauroi³, Vinh Dang¹, Anastasia Frank-Kamenetskii⁴ and Jeremy Morrissette⁵, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴CHOP/UPENN, Philadelphia, PA, ⁵University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) and Macrophage Activation Syndrome (MAS) are associated with highly elevated peripheral blood levels of the inflammasome-activated cytokine IL-18 and…
Abstract Number: 0031 • ACR Convergence 2023
A Systematic Approach for Identifying Causal Variants and Their Target Genes on JIA Risk Haplotypes
Kaiyu Jiang¹, tao liu², Ryan Tewhey³, Susan Kales³, Yungki Park⁴ and James N Jarvis⁵, ¹University at Buffalo, Buffalo, NY, ²Roswell Park Cancer Institute, Buffalo, NY, ³Jackson Laboratories, Bar Harbor, ME, ⁴University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY, ⁵University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: GWAS have identified multiple genetic regions that confer risk for juvenile idiopathic arthritis (JIA).However, identifying the single nucleotide polymorphisms (SNPs) that drive disease risk…
Abstract Number: 0361 • ACR Convergence 2023
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
Leah Medrano and Alice Hoftman, David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…
Abstract Number: 0758 • ACR Convergence 2023
Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease
STEPHANE MITROVIC¹, Arianna De Matteis², Sara Bindoli³, Fabrizio De Benedetti⁴, Bruno Fautrel⁵, Loreto Carmona⁶ and On Behalf Of The Eular/PreS QoC011 Task Force Member⁷, ¹Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, ²IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ³Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, ⁴Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ⁵Sorbonne Université APHP, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) are part of the non-familial (sporadic) systemic inflammatory disorders and are frequently mentioned as…
Abstract Number: 1706 • ACR Convergence 2023
Autoreactive B Cell Responses Are Enriched in Early-onset Oligoarticular Juvenile Idiopathic Arthritis
Claudia Harris¹, Maria Taylor², Ki Pui Lam², Indu Raman³, Chengsong Zhu³, Pui Lee¹, Peter Nigrovic⁴, Erin Janssen⁵, Jing Cui⁶ and Lauren Henderson⁴, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Immunology, Boston Children’s Hospital, Boston, MA, ³Department of Immunology, Microarray & Immune Phenotyping Core Facility, University of Texas, Southwestern Medical Center, Dallas, TX, ⁴Boston Children's Hospital, Boston, MA, ⁵Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: A subset of children with oligoarticular juvenile idiopathic arthritis (oligo JIA) who are anti-nuclear antibody (ANA) positive are known to have dysregulated T cell-B…
Abstract Number: 0035 • ACR Convergence 2023
Using Genotyping and Functional Data from Monocytes to Identify Risk-Driving SNPs on JIA Risk Haplotypes
Emma Haley¹, gilad Barshad², Adam He², Edward J Rice³, Elizabeth Crinzi¹, Marc Sudman⁴, Susan Thompson⁵, Charles G Danko³ and James N Jarvis⁶, ¹Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, ²Cornell University, Ithaca, NY, ³Baker Institute of Animal Health Cornell University, Ithaca, NY, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center/University of Cincinnati College of Medicine, Blue Ash, OH, ⁶University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: GWAS have identified multiple genetic regions that confer risk for juvenile idiopathic arthritis (JIA).However, identifying the single nucleotide polymorphisms (SNPs) that drive disease risk…

« Previous Page
1
…
6
7
8
9
10
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].